This webcast features: Jason Sterling, Principal Scientist and Project Director, Analytical and Formulation Resources, and John Rockwell, Group Leader, Catalent Pharma Solutions Biophysical characterization is critical to understand the make-up and behaviors of biologic therapies and vaccines both early in development and throughout the manufacturing scale-up process. As biologics become more complex in structure, and as scientists improve their understanding of the effects of structure on stability, efficacy, safety, etc., there is a need to develop new and improved analytical…
Friday, December 11, 2020 Daily Archives
Boehringer Ingelheim re-enters ADC space with $1.4bn NBE buy
Having already dabbled in the antibody-drug conjugate (ADC), Boehringer Ingelheim has gone full in, acquiring NBE-Therapeutics for €1.18 billion ($1.4 billion). The deal sees German biopharma firm Boehringer Ingelheim agree to buy private Swiss biotech NBE-Therapeutics, adding an ADC technology platform and a lead compound NBE-002 in Phase I clinical studies for triple negative breast cancer and other solid tumors. When the deal closes – expected in Q1 2021 – “NBE Therapeutics with its team of highly qualified scientists will…
Sartorius: $36m WaterSep buy to further boost filtration ambition
Sartorius will bolster its downstream offering by adding hollow‑fiber membrane manufacturer WaterSep BioSeparations. The deal comes a month after Sartorius closed its €360 million acquisition of BIA Separations, Bioprocess vendor Sartorius Stedim Biotech announced this week it will pay $27 million for Marlborough, Massachusetts-based purification firm WaterSep BioSeparations, with a further $9 million to be paid depending on a defined sales revenue growth by 2023. WaterSep makes hollow-fiber membrane devices and pre-sterilized assemblies for upstream and downstream biopharmaceutical applications. “The…